Related Experiment Video

Updated: Aug 30, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure

Christian Stumpf1, Christoph Lehner, Saeed Eskafi

  • 1Laboratory for Molecular Cardiology, Medical Clinic II, University of Erlangen-Nuremberg, Schwabachanlage 10, Ostfluegel, UG, Erlangen 91054, Germany. ch.stumpf@web.de

European Journal of Heart Failure
|November 11, 2003
PubMed

Insights

Chronic heart failure (CHF) patients show higher levels of CD154 on platelets, suggesting this immune molecule contributes to inflammation in heart failure. Aspirin did not affect these levels.

Area of Science:

  • Cardiology
  • Immunology
  • Pathophysiology

Background:

  • Inflammation is a key factor in chronic heart failure (CHF) pathogenesis.
  • Elevated proinflammatory cytokines and immune activation are observed in CHF patients.
  • CD154, an immune modulator, is implicated in vascular events like thrombosis and inflammation.

Purpose of the Study:

  • To investigate the role of CD154 in the development and progression of CHF.
  • To examine CD154 expression on platelets in CHF patients compared to healthy controls.

Main Methods:

  • Flow cytometry was used to analyze platelet-bound CD154 and P-selectin expression.
  • Fifty CHF patients and 15 healthy controls were studied.
  • The influence of aspirin therapy on CD154 expression was assessed.

Main Results:

  • CHF patients exhibited significantly higher expression of platelet-bound CD154 and P-selectin compared to controls.
  • CD154 expression on platelets positively correlated with CHF severity (NYHA class).
  • No significant differences in soluble CD154 or monocyte CD40 expression were found; aspirin did not alter platelet CD154 or P-selectin levels.

Conclusions:

  • Elevated CD154 on platelets in CHF patients suggests its involvement in the inflammatory processes of heart failure.
  • The CD40-CD154 axis may play a pathogenic role in CHF development and progression.
Abstract

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...